Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools
by Dominic Tyer
Will work with therapeutic companion software company Voluntis
Sanofi has expanded it alliance with a French therapeutic companion software company to develop a new mobile app for insulin patients.
The tool, which Sanofi characterises as a ‘digital insulin titration solution’, will be a mobile app that assists type 2 diabetes patients on basal insulin with decision-making and self-management.
The app will allow remote monitoring by a patient’s health care team and is set to be piloted in North America and several European countries.
Voluntis focuses on ‘embedding connectivity in therapeutics and medical intelligence in software’ and last year gained FDA clearance and the European CE mark for the new mobile app.
"Despite the availability of new medicines for the treatment of diabetes, we see thatoutcomes are not sufficiently improving and that more than half of patients are not well controlled,"
Peter Guenter, executive vice-president, diabetes and cardiovascular at Sanofi, said: "Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognise that the right tools need to be developed to realise better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal."
The new agreement expands Sanofi’s existing alliance with Voluntis, which was established in 2011 and has seen the partners develop the Diabeo digital device to help patients manage their basal-bolus treatment.
Eric Elliott, chairman of Voluntis, said: "This new phase of our partnership with a world leader in diabetes will help us deliver digital titration tools into the hands of providers and their patients. F
“Furthermore, digital therapeutics allow manufacturers and payers to check whether agreed value metrics have been achieved and help to lower costs without compromising on patient outcomes and access. They ensure that prescription medications deliver the effects for which they were brought to market."